Dr. Prem Soman
Nuclear Medicine (Nuclear Cardiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 580
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nuclear Cardiology Physician primary
PA license MD426292
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- UPMC PAssavant Pittsburgh, PA
- UPMC St Margaret Pittsburgh, PA
- UPMC Altoona Altoona, PA
Medical groups
- University of Pittsburgh Physicians (4,236 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 580
- Services billed
- 851
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 368 | 327 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 94 | 94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 92 | 92 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 62 | 62 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 38 | 20 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 37 | 37 |
| Established patient office or other outpatient visit, 30-39 minutes | 35 | 32 |
| Established patient office or other outpatient visit, 40-54 minutes | 33 | 31 |
| Nuclear medicine study of heart muscle blood flow by pet | 17 | 17 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vyndamax (tafamidis) | 964 |
| Eliquis (apixaban) Other prescribers in Pittsburgh, PA | 128 |
| Spironolactone Other prescribers in Pittsburgh, PA | 101 |
| Vyndaqel (tafamidis meglumine) | 90 |
| Torsemide Other prescribers in Pittsburgh, PA | 79 |
| Jardiance (empagliflozin) Other prescribers in Pittsburgh, PA | 74 |
| Rosuvastatin Calcium Other prescribers in Pittsburgh, PA | 68 |
| Atorvastatin Calcium Other prescribers in Pittsburgh, PA | 53 |
| Metoprolol Succinate Other prescribers in Pittsburgh, PA | 49 |
| Furosemide Other prescribers in Pittsburgh, PA | 38 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 10 payments worth $20,815 in total to this clinician.
| Pfizer Inc. | $17,065 |
|---|---|
| Alnylam Pharmaceuticals Inc. | $3,750 |
| Consulting Fee | $16,425 |
|---|---|
| Travel and Lodging | $2,318 |
| Compensation for services other than consulting (speaking, faculty) | $2,072 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Nov 10, 2025 | Consulting Fee VYNDAQEL · CARDIOVASCULAR | $5,200 |
| Pfizer Inc. Jan 7, 2025 | Consulting Fee | $4,875 |
| Alnylam Pharmaceuticals Inc. Jun 27, 2025 | Consulting Fee ONPATTRO · Genetic Disease | $3,750 |
| Pfizer Inc. Nov 10, 2025 | Consulting Fee VYNDAQEL · CARDIOVASCULAR | $2,600 |
| Pfizer Inc. Feb 7, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $1,300 |
| Pfizer Inc. Feb 24, 2025 | Travel and Lodging travel to CHICAGO, IL | $859 |
| Pfizer Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $772 |
| Pfizer Inc. Nov 8, 2025 | Travel and Lodging VYNDAMAX · CARDIOVASCULAR · travel to New Orleans, LA · in-kind | $562 |
| Pfizer Inc. Nov 8, 2025 | Travel and Lodging VYNDAMAX · CARDIOVASCULAR · travel to New Orleans, LA · in-kind | $505 |
| Pfizer Inc. Feb 24, 2025 | Travel and Lodging VYNDAQEL · CARDIOVASCULAR · travel to CHICAGO, IL · in-kind | $392 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $25,431 in research payments for these studies, mostly to the institutions running them.
- Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Eidos Therapeutics, Inc. · Active, not recruiting · NCT04988386
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.